ORIC Stock Analysis: Oric Pharmaceuticals | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 881m USD | 12M Return: -32.9% | US68622P1093 | Charts, Fundamentals & Technical Analysis

Oncology, Kinase Inhibitors, Epigenetic Modulators, Prostate Cancer
Total Rating 14
Safety 62
Buy Signal -0.49
Biotechnology
Sub-Industry Rotation: +2.7
Market Cap: 881M
Avg Turnover: 14.6M
Risk 3d forecast
Volatility79.2%
VaR 5th Pctl12.7%
VaR vs Median-3.00%
Reward TTM
Sharpe Ratio0.01
Rel. Str. IBD6.2
Rel. Str. Peer Group11.8 pctl
Character TTM
Beta2.034
Beta Downside1.716
Hurst Exponent0.443
Choppyness69.3%
Drawdowns 3y
Max DD73.46%
CAGR/Max DD0.01
CAGR/Mean DD0.03
EPS (Earnings per Share) EPS (Earnings per Share) of ORIC over the last years for every Quarter: "2021-09": -0.47, "2021-12": -0.58, "2022-03": -0.59, "2022-06": -0.51, "2022-09": -0.63, "2022-12": -0.52, "2023-03": -0.53, "2023-06": -0.5, "2023-09": -0.44, "2023-12": -0.49, "2024-03": -0.37, "2024-06": -0.45, "2024-09": -0.49, "2024-12": -0.51, "2025-03": -0.42, "2025-06": -0.47, "2025-09": -0.33, "2025-12": -0.3, "2026-03": -0.34, "2026-06": -0.38,
Last SUE: -0.40
Qual. Beats: 0
Revenue Revenue of ORIC over the last years for every Quarter: 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 1.538, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 1.066, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0, 2026-03: 0, 2026-06: 0,
Last SUE: 0.00
Qual. Beats: 0

Warnings

Strong Share Dilution
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 6.5 years of data, until 10/2026

Jan +4.2% 0
Feb -2.7% 0
Mar -14.5% 22
Apr -18.1% 22
May +0.1% 0
Jun +21.2% 11
Jul -1.4% 11
Aug +1.1% 0
Sep +0.3% 11
Oct -12.5% 11
Nov +10.2% 22
Dec +5.7% 5

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: ORIC Oric Pharmaceuticals

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that address resistance mechanisms in cancer. Its lead pipeline candidates include enozertinib (ORIC-114), a brain-penetrant irreversible inhibitor targeting EGFR and HER2 exon 20 insertion mutations, and rinzimetostat (ORIC-944), an allosteric inhibitor of polycomb repressive complex 2 being studied for prostate cancer. Both candidates are currently in Phase 1b clinical trials. The company has established clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson to evaluate ORIC-944 in combination with their respective androgen receptor inhibitors, Nubeqa and Erleada. ORIC was incorporated in 2014 and is headquartered in South San Francisco, California.

As a clinical-stage oncology biotech, ORIC operates in a sector where companies typically have no approved products or commercial revenue, relying instead on capital markets, partnerships with larger pharmaceutical firms, and licensing arrangements to fund lengthy and expensive drug development programs. The use of collaboration and supply agreements with established players like Bayer and Johnson & Johnson is a common strategy for smaller biotechs to share development risk and access complementary compounds for combination regimens.

Headlines to Watch Out For
  • Enozertinib Phase 1b EGFR exon 20 data readout
  • ORIC-944 prostate cancer combination data with Bayer and J&J
  • Cash runway supports pipeline through key 2025 catalysts
Piotroski VR-10 (Strict) 0.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.28 > 0.02 and ΔFCF/TA 7.27 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.28 > 3% & CFO -111.6m > Net Income -140.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 13.19 > 1.5 & < 3
Outstanding Shares: last quarter (108.0m) vs 12m ago 38.25% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.31%; Δ -0.31% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' 10.00
A: 0.63 (Total Current Assets 273.7m - Total Current Liabilities 20.8m) / Total Assets 404.7m
B: -1.90 (Retained Earnings -769.5m / Total Assets 404.7m)
C: -0.38 (EBIT TTM -144.2m / Avg Total Assets 375.8m)
D: 16.27 (Book Value of Equity 381.3m / Total Liabilities 23.4m)
Altman-Z'' = 12.41 = AAA
What is the price of ORIC shares?

As of November 20, 2026, the stock is trading at USD 7.70 with a total of 1,065,904 shares traded. Over the past week, the price has changed by -9.41%, over one month by -39.47%, over three months by -47.44% and over the past year by -32.93%.

Current recommended Stop Loss: 6.70 (which is 13% or 1.3 ATR below the current price).

Is ORIC a buy, sell or hold?

Oric Pharmaceuticals has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy ORIC.

  • StrongBuy: 12
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ORIC price?
Analysts Target Price 21.7 181.9%
Oric Pharmaceuticals (ORIC) - Fundamental Data Overview as of 14 November 2026
Market Cap USD = 881.0m (881.0m USD * 1.0 USD.USD)
P/B = 2.4414
Revenue TTM = 0.0 USD
EBIT TTM = -144.2m USD
EBITDA TTM = -143.0m USD
 Long Term Debt = unknown (0.0)
 Short Term Debt = 3.33m USD (from shortTermDebt, last quarter)
Debt = 3.33m USD (from shortLongTermDebtTotal, last quarter) (leases 3.33m already included)
Net Debt = -261.4m USD (calculated: Debt 3.33m - CCE 264.8m)
Enterprise Value = 619.6m USD (881.0m + Debt 3.33m - CCE 264.8m)
 Interest Coverage Ratio = unknown (Ebit TTM -144.2m / Interest Expense TTM 0.0)
 EV/FCF = -5.51x (Enterprise Value 619.6m / FCF TTM -112.4m)
FCF Yield = -18.14% (FCF TTM -112.4m / Enterprise Value 619.6m)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.22m) / Revenue TTM)
 Tobins Q-Ratio = 1.53 (Enterprise Value 619.6m / Total Assets 404.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 3.33m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -113.9m (EBIT -144.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.19 (Total Current Assets 273.7m / Total Current Liabilities 20.8m)
Debt / Equity = 0.01 (Debt 3.33m / totalStockholderEquity, last quarter 381.3m)
 Debt / EBITDA = 1.83 (negative EBITDA) (Net Debt -261.4m / EBITDA -143.0m)
 Debt / FCF = 2.33 (negative FCF - burning cash) (Net Debt -261.4m / FCF TTM -112.4m)
 Total Stockholder Equity = 397.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.35% (Net Income -140.4m / Total Assets 404.7m)
RoE = -35.35% (Net Income TTM -140.4m / Total Stockholder Equity 397.0m)
RoCE = -36.31% (EBIT -144.2m / Capital Employed (Equity 397.0m + L.T.Debt 0.0))
 RoIC = -29.41% (negative operating profit) (NOPAT -113.9m / Invested Capital 387.3m)
 WACC = 12.41% (E(881.0m)/V(884.4m) * Re(12.46%) + D(3.33m)/V(884.4m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.94 | Cagr: 23.36%
 [DCF] Fair Price = unknown (Cash Flow -112.4m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.40 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.38 | Chg30d=-1.41% | Revisions=+0% | Analysts=13
EPS current Year (2026-12-31): EPS=-1.49 | Chg30d=-0.59% | Revisions=+0% | GrowthEPS=-1.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.69 | Chg30d=-2.14% | Revisions=+0% | GrowthEPS=-13.0% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +0% (up=3, down=3)